Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • Non-Hodgkin Lymphoma • CAR-T • Hematology • DLBCL
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? Within classes are there any criteria by which you select a specific product?
Answer from: Medical Oncologist at Academic Institution
If a patient relapses after an autologous stem cell transplant and is a candidate for CAR T-cell therapy, I would proceed with CAR T-cell therapy given longer follow up compared to bispecific antibodies, and thus a portion of the patient can achieve a durable complete response. For patients that rel...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In general, several factors are considered for advanced lines of therapies. From the disease standpoint, in certain forms of aggressive DLBCL, CAR T cells have a role. However, in very aggressive forms, the vein-to-vein time for CAR T cells might be just too long to be an option. Thus, off-the-shelf...